NCT03895385View on ClinicalTrials.gov

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

October 4, 2019

Study Completion Date

October 4, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Bimekizumab

Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.

Trial Locations (1)

78209

Up0034 001, San Antonio

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03895385 - A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects | Biotech Hunter | Biotech Hunter